[{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates a Phase Ib\/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"GL Mountrose Investment Two","pharmaFlowCategory":"D","amount":"$169.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS\u00ae in Patients with MET Amplified Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO at the 2022 WCLC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed\/Refractory Follicular Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Updated Phase II Savolitinib \/ Imfinzi\u00ae Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchison China MediTech"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchison China MediTech"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchison China MediTech"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med to Highlight Clinical Data on Lead Products at the Upcoming ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchison China MediTech"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchison China MediTech"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Orpathys (savolitinib), is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors.
HMPL-453 is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth (through tissue growth and repair), promotion of angiogenesis and resistance to anti-tumor therapies.
HMPL-689 (amdizalisib) is a novel, selective and potent oral inhibitor targeting the isoform PI3K delta. PI3K delta is a target for drugs that aim to prevent or treat hematologic cancer.
Savolitinib (ORPATHYS), is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors, blocks atypical activation of MET receptor tyrosine kinase pathway.
The Phase II trial is an open-label, two-cohort, multi-center study to evaluate the efficacy, safety and pharmacokinetics (“PK”) of ORPATHYS® in locally advanced or metastatic GC or GEJ patients whose disease progressed after at least one line of standard therapy.
This trial is to explore potential synergistic activity of the novel, oral angio-immuno kinase inhibitor surufatinib with the anti-PD-1 antibody tislelizumab in enhancing overall antitumor activity from inhibition of angiogenesis along with stimulation of an immune response.
China MediTech Limited will sell its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), a non-core and non-consolidated OTC drug joint venture business which includes Osimertinib.
final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer (WCLC 2020).
New and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming ASCO20 Virtual Scientific Program.